<DOC>
	<DOC>NCT00846976</DOC>
	<brief_summary>This is an open label, single-centered treatment protocol designed to monitor the safety of patients treated with a 200 mg daily dose of CASODEX. Patient will receive CASODEX as long as physician feels that he is benefiting from this form of therapy.</brief_summary>
	<brief_title>Treatment Protocol to Monitor the Safety of a 200 mg Dose of Bicalutamide in Patients With Advanced Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<criteria>Histologically or cytologically confirmed adenocarcinoma of the prostate gland Patients with advanced prostate cancer Adult male over the age of 18 years old Normal liver function (AST &lt; 2 x Upper Limit Normal) ECOG performance status of 4. Previous history or presence of another malignancy other than prostate cancer or treated squamous/basal cell carcinoma of the skin, within the last 5 years.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Safety</keyword>
</DOC>